Compare Match Group Inc (MTCH) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs Novo Nordisk A/S — how do they compare? Match Group Inc trades at $41.28 (market cap $9.53B), while Novo Nordisk A/S trades at $38.48 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 17.3× Match Group Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Match Group Inc for 115 Days and Novo Nordisk A/S for 116 Days on average.
| MTCH | NVO | |
|---|---|---|
Market Cap | $9.53B | $165.31B |
Volume | 3,228,794 | 11,432,838 |
Sector | Media | Health |
52-Week High | $44.40 | $63.98 |
52-Week Low | $28.90 | $35.29 |
Typical Hold Time | 115 Days | 116 Days |
Enterprise Value | $12.49B | $179.56B |
Dividend Yield | 1.93% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $41.48, up 1.52% today, near the consensus price target of $42.29. The stock shows a bullish technical trend with strong moving averages, though RSI indicates potential overbought conditions. Fundamentally, the company maintains robust profitability with a 20.17% net income margin and positive cash flow trends, while recent earnings have been mixed with a beat in Q2 2026 but a miss in Q1 2026. Positive sentiment is driven by product innovation at Tinder and growth from Hinge.
The outlook for MTCH is positive, supported by analyst consensus leaning buy (53% of ratings) and a projected EPS beat in Q3 2026. Investment opportunities include margin expansion and AI-driven product enhancements, but risks involve high debt levels and competitive pressures in the dating app market. Shareholder value may benefit from sustained cash flow generation and strategic initiatives.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
